Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and …
Drug-drug interactions (DDIs) arising from the perturbation of drug metabolising enzyme
activities represent both a clinical problem and a potential economic loss for the …
activities represent both a clinical problem and a potential economic loss for the …
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Diabetes mellitus is a disease that affects millions of people worldwide and its prevalence is
estimated to rise in the future. Billions of dollars are spent each year around the world in …
estimated to rise in the future. Billions of dollars are spent each year around the world in …
Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
N Rosenthal, G Meininger, K Ways… - Annals of the New …, 2015 - Wiley Online Library
The sodium glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin is a novel treatment
option for adults with type 2 diabetes mellitus (T2DM). In patients with hyperglycemia …
option for adults with type 2 diabetes mellitus (T2DM). In patients with hyperglycemia …
Clinical pharmacokinetic, pharmacodynamic, and drug–drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor
D Devineni, D Polidori - Clinical pharmacokinetics, 2015 - Springer
The sodium-glucose co-transporter 2 (SGLT2) inhibitors represent novel therapeutic
approaches in the management of type 2 diabetes mellitus; they act on kidneys to decrease …
approaches in the management of type 2 diabetes mellitus; they act on kidneys to decrease …
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping
Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily contribute to the
elimination of drugs from almost all therapeutic classes. Awareness of the importance of …
elimination of drugs from almost all therapeutic classes. Awareness of the importance of …
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
J Solomon, MC Festa, YS Chatzizisis… - Pharmacology & …, 2023 - Elsevier
Diabetes drives an increasing burden of cardiovascular and renal disease worldwide,
motivating the search for new hypoglycemic agents that confer cardiac and renal protective …
motivating the search for new hypoglycemic agents that confer cardiac and renal protective …
Sodium–glucose cotransporter 2 inhibitors: a case study in translational research
AL Beitelshees, BR Leslie, SI Taylor - Diabetes, 2019 - Am Diabetes Assoc
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are the most recently approved class of
diabetes drugs. Unlike other agents, SGLT2 inhibitors act on the kidney to promote urinary …
diabetes drugs. Unlike other agents, SGLT2 inhibitors act on the kidney to promote urinary …
Canagliflozin prevents lipid accumulation, mitochondrial dysfunction, and gut microbiota dysbiosis in mice with diabetic cardiovascular disease
Type 2 diabetes mellitus (T2DM) is associated with cardiovascular disease (CVD) and
sodium glucose cotransporter 2 inhibitors, as oral medications for T2DM treatment have …
sodium glucose cotransporter 2 inhibitors, as oral medications for T2DM treatment have …
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus
GL Plosker - Drugs, 2014 - Springer
Canagliflozin (Invokana™) is an orally administered sodium-glucose co-transporter-2
(SGLT2) inhibitor used in the treatment of patients with type 2 diabetes. By inhibiting the …
(SGLT2) inhibitor used in the treatment of patients with type 2 diabetes. By inhibiting the …
The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice
Sodium-glucose cotransporter 2 inhibitors such as canagliflozin lower blood glucose and
reduce cardiovascular events in people with type 2 diabetes through mechanisms that are …
reduce cardiovascular events in people with type 2 diabetes through mechanisms that are …